Premium
Clinical efficacy of an α 1A/D ‐adrenoceptor blocker (naftopidil) on overactive bladder symptoms in patients with benign prostatic hyperplasia
Author(s) -
TAKAHASHI SATORU,
TAJIMA ATSUSHI,
MATSUSHIMA HISASHI,
KAWAMURA TAKESHI,
TOMINAGA TAKASHI,
KITAMURA TADAICHI
Publication year - 2006
Publication title -
international journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.172
H-Index - 67
eISSN - 1442-2042
pISSN - 0919-8172
DOI - 10.1111/j.1442-2042.2006.01222.x
Subject(s) - nocturia , medicine , overactive bladder , urology , international prostate symptom score , hyperplasia , lower urinary tract symptoms , prostate , urinary system , alternative medicine , pathology , cancer
Aim: We evaluated the efficacy of an α 1a/d blocker, naftopidil, on storage symptoms in patients with benign prostatic hyperplasia (BPH), using frequency/volume charts (FVC). Methods: A total of 81 patients with BPH (52–91 years, mean age 69.0 years) were studied. The inclusion criteria were: (i) one or more episode(s) of urinary urgency/day; (ii) a score of eight or more points on the International Prostate Symptom Score (I‐PSS); and (iii) three or more points in any of the scores for three items (frequency, nocturia, and urgency) of the I‐PSS. The patients received 50–75 mg/day of naftopidil for 6 weeks. All the patients were examined for 2‐day FVC before and after the administration of naftopidil. I‐PSS, quality of life index, and uroflowmetry were also evaluated. Results: Total I‐PSS decreased from 19.1 to 10.5 points ( P < 0.0001), with significant improvement of both storage and voiding symptom scores ( P < 0.0001, both). The score for urgency decreased from 3.1 to 1.4 ( P < 0.0001). Daytime and night‐time frequency decreased from 9.3 to 8.0 ( P < 0.0001) and from 2.7 to 2.0 ( P = 0.0009), respectively. Mean volume/void increased from 174.0 to 188.6 mL ( P = 0.0453). Nocturia decreased from 3.2 to 2.3 ( P < 0.0001) in 40 patients who suffered from nocturia two times or more. Notably, significant improvement of nocturia was observed in the patients both with and without nocturnal polyuria ( P = 0.0006 and 0.0135, respectively). Conclusion: The α 1a/d blocker naftopidil improves not only voiding symptoms but also storage symptoms, and is effective for nocturia in patients with BPH regardless of the existence of nocturnal polyuria.